臨床神経学

<シンポジウム34―5>脳梗塞:Tissue clockとReperfusion

脳梗塞急性期治療のtherapeutic time window

阿部 康二

岡山大学神経内科〔〒700―8558 岡山市北区鹿田町2―5―1〕

Neuroprotection is essential for therapy in acute stage of stroke. Both neurotrophic factors (NTFs) and free radical scavenger can be such neuroprotective reagents with inhibiting death signals and potentiating survival signals under cerebral ischemia. Edaravone, a free radical scavenger, is the first clinical drug for neuroprotection in the world which has been used from 2001 in most ischemic stroke patients in Japan. Edaravone scavenges hydroxyl radicals both in hydrophilic and hydrophobic conditions, and is especially useful in thrombolytic therapy with tissue plasminogen activator (tPA). Combination therapy of Edaravone with tPA greatly increased survival of stroke animals, reduced infarct size, and inhibited molecular markers of oxidative damage in lipid, protein and DNA. Use of Edaravone greatly reduced hemorrhagic transformation accompanied by tPA treatment, and may also extend therapeutic time window with tPA therapy for more than 3 hr in human stroke patients.
Full Text of this Article in Japanese PDF (526K)

(臨床神経, 51:1182−1184, 2011)
key words:脳保護療法,エダラボン,tPA,出血合併症

(受付日:2011年5月20日)